This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Valeant Pharmaceuticals International, Inc.
Drug Names(s): Eye001, pegaptanib sodium
Description: Macugen is a pegylated RNA aptamer against VEGF-165 (major VEGF isoform implicated in anagiogenesis). Binding of the aptamer (a single stranded nucleic acid) to VEGF-165 prevents interaction with the VEGF receptor. Macugen is delivered by intravitreal injection in the eye. Macugen is the first RNA aptamer in human clinical trials.
Revenue splits for this drug are BioMedTracker estimates.
Gilead and Eyetech
In March 2000, Gilead entered into an agreement with EyeTech relating to Macugen. Gilead invented the compound upon which Macugen is based, NX 1838, using SELEX technology licensed to Gilead from ULEHI. Gilead then licensed NX 1838 to EyeTech who further developed it into Macugen. Under its license from Gilead, EyeTech is required to pay Gilead fees and milestone payments, as well as a percentage of any revenue EyeTech generates from worldwide sales of Macugen. Gilead is required to pay a portion on its royalties to the University of Colorado, Boulder. Gilead has indicated it will receive a net royalty percentage in the high single digits of net sales.
The agreement with EyeTech expires upon the later of ten years after first commercial sale of any product developed, or the date the last patent expires under the agreement. EyeTech granted Pfizer a sublicense relating to Macugen in...See full deal structure in Biomedtracker
Partners: Nektar Therapeutics Gilead Sciences, Inc. Pfizer Inc. Ionis Pharmaceuticals, Inc. DRI Capital Inc. Enzon Pharmaceuticals, Inc.
Additional information available to subscribers only: